Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8857751.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We studied the effect of olanzapine (1 to 15 mg/d) in 15 nondemented parkinsonian patients with drug-induced psychosis. Psychotic symptoms decreased significantly during treatment, and there was no worsening of extrapyramidal symptoms. These results suggest that olanzapine is a well-tolerated and effective treatment for drug-induced psychosis in nondemented patients with Parkinson's disease.
Medical subject headings
- Antipsychotic Agents
- Parkinson Disease
- Pirenzepine
- Psychotic Disorders